XBI
All
Newsflash
Article
-
Analysis suggests that the State Street SPDR S&P Biotech ETF (XBI) is poised to outperform the iShares Global Healthcare ETF (IXJ) in 2026.
The analysis points out that while the iShares Global Healthcare ETF (IXJ) has performed better over the past five years, the State Street SPDR S&P Biotech ETF (XBI) has outperformed IXJ year-to-date,
-
Analysis suggests that the State Street SPDR S&P Biotech ETF (XBI) is poised to outperform the iShares Global Healthcare ETF (IXJ) in 2026.
The analysis points out that while the iShares Global Healthcare ETF (IXJ) has performed better over the past five years, the State Street SPDR S&P Biotech ETF (XBI) has outperformed IXJ year-to-date,
- No data
XBI
Svmuu provides news and information related to XBI, as well as real-time data on XBI. We provide in-depth analysis and interpretation of the latest XBI developments, helping investors stay informed about XBI policy updates. Svmuu is your essential tool for keeping up with the latest XBI trends! Here, we’ll join you in keeping a close eye on XBI news and use a clear macro perspective to make sense of the uncertain future of crypto.
24H Trending
-
1
The Nikkei 225 Index fell 5.76% from its previous close, currently trading at 57,557.09.
-
2
ZEC (Zcash) is up 6.26% over the past 4 hours, currently trading at $1,330.13.
-
3
Taiwan Stock Exchange Weighted Index fell 6.11% from its previous close, currently trading at 39,032.95.
-
4
The Shanghai Composite Index fell 1.06% from its previous close, currently trading at 3,650.85.
-
5
South Korea's KOSPI index fell 5.48% from its previous close, currently standing at 5,088.79.
-
6
SK hynix fell 12.42% from its previous close, currently trading at ₩1,107,000.
-
7
Samsung Electronics fell 9.98% from its previous close, currently trading at ₩181,400.
-
8
Waller Street Hedge Funds Log Record Unwinding Rate and Heavy Layoffs Last Month
-
9
Nikkei Stock Average drops 5.9% to 57,497.16, dragged by chip stocks amid U.S. tech selloff
-
10
Former JPMorgan Chase wealth advisors Phil Scott and Jim Atwood, who left to launch their own independent firm after refusing to trim their AI stockholdings, are now facing a market test.
Markets Today
Recommended Reading
